Chlorpromazine17 | Placebo | Movement disorders ⇑ (RR=3; CI 1.3 to 8) | Improved ⇑ (RR=1.6; CI 1.3 to 1.8) | Improved ⇑ (RR=2; CI 1.8 to 2.4) | Relapse ⇓ (RR=0.6; CI 0.5 to 0.7) |
1646 participants | 1470 participants | | Relapse ⇓ (RR=0.3; CI 0.1 to 0.8) | Relapse ⇓ (RR=0.5; CI 0.4 to 0.6) | Attrition ⇔ (RR=1.0; CI 0.7 to 1.6) |
| | | Attrition ⇓ (RR=0.7; CI 0.6 to 0.9) | Attrition ⇓ (RR=0.6; CI 0.5 to 0.8) | Movement disorders ⇑ (RR=2.8; CI 1.4 to 6) |
| | | Movement disorders ⇑ (RR=1.8; CI 1.1 to 4.7) | Movement disorders ⇑ (RR=2; CI 1.5 to 2.7) | Weight ⇑ (OR=5; CI 2 to 10) |
| | | | Sedation ⇑ (RR=2.3; CI 1.8 to 3) | |
Zuclopenthixol acetate26 | Chlorpromazine, haloperidol, clothiapine | Improved ⇔ (RR=1; CI 0.9 to 1.1) | | | |
234 participants | 179 participants | Requiring re-dosing ⇔ (RR=1.5; CI 0.8 to 2.9) | | | |
| | Attrition ⇔ (RR=0.7; CI 0.2 to 2.1) | | | |
Haloperidol decanoate23 | Oral haloperidol | | | Improved ⇔ (RR=0.9; CI 0.6 to 1.4) | |
11 participants | 11 participants | | | | |
Haloperidol decanoate23 | Other depots | | | Relapse ⇔ (RR=1.2; CI 0.7 to 1.9) | |
187 participants | 184 participants | | | Attrition ⇔ (RR=0.9; CI 0.6 to 1.4) Movement disorders ⇔ (RR=0.9; CI 0.8 to 1.1) |